in the first clinical trial in the world from Norway with interest.
Although the authors acknowledge that more work must be done with larger trials,
the intial small trial is welcome news to the CFIDS/ME community
worldwide. Two years ago, retuximab was first suggested as possibly being helpful
for those with this illness by Dr. Yoshitsugi Hokama, a researcher (now
Professor Emeritus) from the University of Hawaii's John A. Burns School of
Medicine while being funded by the National CFIDS Foundation along with our
federal NIH. The suggestion can be seen at the end of the article on the
ciguatera assay PDF on our website. The assay has, via fully replicated
science, become the first biomarker for autoimmune diseases and thousands of ME
patients worldwide have tested positive to date. The testing protocol is
available on our website. The article suggesting retuximab can be seen
here:
_http://www.ncf-net.org/pdf/AnticardiolipinAntibodies.pdf_
(http://www.ncf-net.org/pdf/AnticardiolipinAntibodies.pdf)
Our all-volunteer charity will continue to pursue the cause of CFIDS/ME as
our priority with all donations going toward research with no percentage
held back.
For better health,
Gail Kansky
President, National CFIDS Foundation, Inc.
103 Aletha Rd.
Needham, MA 02492-3931
781-449-3535
_http://www.ncf-net.org_ (http://www.ncf-net.org)
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Too much mail? Try a digest version. See http://www.co-cure.org/digest.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
